Biomarkers, Rescue, and Choosing a Regimen | AI Learning Guide

Look at how the scenario is argued, because the structure of the argument is the point. First, the tumor's BRCA mutation tells us which vulnerability to exploit: cells that cannot repair double-strand breaks by homologous recombination. Second, the platinum agent supplies lesions those cells cannot fix, and the PARP inhibitor removes the backup single-strand-break route, so escaping both would require restoring homologous recombination. Third, the constraint is named honestly: both drugs suppress the marrow, so the combination cannot be given at full dose of each. Notice that the justification comes from the tumor's molecular defect and the limit comes from the normal-tissue curves. That is the whole course in one decision.

0:00 / 0:00

Auto-play

Why a biomarker is not optional here

A synthetic-lethal strategy depends on the tumor actually carrying the defect the drug exploits. BRCA mutation testing identifies the subgroup in which the PARP inhibitor's selectivity window is wide. Given to an unselected population, most tumors retain homologous recombination, the average benefit falls, and the measured therapeutic index looks worse than it is in the subgroup that would benefit.

Widening from the normal-tissue side

Rescue agents and supportive care do not change the drug's molecular selectivity. They lower the normal-tissue curve or shorten the time the patient spends below a safe blood count, which raises the dose that can be delivered. A higher tolerated dose is a wider window.

A BRCA-mutant tumor: justifying the regimen

The tumor carries a confirmed BRCA mutation and the disease burden requires rapid cytoreduction. A platinum agent generates DNA lesions that BRCA-deficient cells cannot repair by homologous recombination; a PARP inhibitor blocks the remaining single-strand-break repair route. The mechanisms are complementary rather than overlapping, so a cell would need to restore homologous recombination to escape both. The constraint is toxicity: both agents suppress the bone marrow, so the combination is given with close monitoring and dose adjustment rather than at full dose of each.

What would change the decision

If the BRCA mutation were absent, the PARP inhibitor would lose its rationale and the platinum would be judged on its own therapeutic index. If the patient's marrow reserve were already poor, the overlapping myelosuppression would dominate and a non-overlapping partner would be preferred. The regimen is justified by the tumor's molecular defect and constrained by the normal-tissue curves.